Archives of Gynecology and Obstetrics

, Volume 285, Issue 3, pp 579–584 | Cite as

Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study

  • Şerif Ercan
  • Özge Kaymaz
  • Nihal Yücel
  • Asuman Orçun
Maternal-Fetal Medicine



Although cancer diagnosed during pregnancy is rare, the coexistence of pregnancy and malignancy becomes more common in view of prolongation of reproductive age. Therefore, it is important that the specificity of a tumor marker be evaluated during pregnancy to avoid misinterpretation in the follow-up of a pregnant cancer patient. The present study aims to investigate the serum concentrations of CA-125, CA 15-3, CA 19-9 and CEA in healthy pregnant women through gestation.


In this prospective study, we followed thirty healthy pregnant women. Blood samples were obtained during each trimester of pregnancy (10–12, 22–24 and 34–36 weeks). The maternal serum levels of CA-125, CA 15-3, CA 19-9 and CEA were measured using electrochemiluminescence immunoassay.


There was no difference between the first and second trimester serum levels of CA 125, CEA and CA 19-9. However, serum CA 125 levels in third trimester were found to be significantly elevated in pregnants compared to the second trimester (median values 19.6 vs. 15.6 IU/mL, p = 0,009). Similarly, the serum CEA levels in third trimester were significantly higher than those of second trimester (median values 1.1 vs. 0.7 ng/ml, p = 0.001). It is also found that CEA and CA 19-9 assay values were significantly elevated in the third trimester of pregnancy when compared with the first trimester of pregnancy (CEA median values 1.1 vs. 0.7 ng/ml, p = 0.02 and CA 19-9 median values 11.6 vs. 7.7 IU/mL, p = 0,02). Three trimester had statistically similar levels for serum CA 15-3 (median values 17.5, 19.7 and 18.3 U/mL, respectively). The four tumor markers assay values were found generally within the normal range.


These findings suggest that maternal serum levels of CA 125, CEA and CA 19-9 were increased during third trimester of pregnancy. However, these elevations were within the normal range. CA 15-3 is independent of gestation and reliable tumor markers in monitoring malignancy in pregnant patients.


Pregnancy Tumor markers CA 125, CA 15-3 CA 19-9 Carcinoembryonic antigen 


  1. 1.
    Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44(2):151–178PubMedCrossRefGoogle Scholar
  2. 2.
    Schlageter MH, Larghero J, Cassinat B, Toubert ME, Borschneck C, Rain JD (1998) Serum Carcinoembryonic Antigen, Cancer Antigen 125, Cancer Antigen 15–3, Squamous Cell Carcinoma, and Tumor-associated Trypsin Inhibitor Concentrations during Healthy Pregnancy. Clin Chem 44(9):1995–1998PubMedGoogle Scholar
  3. 3.
    Cheli CD, Morris DL, Neaman IE, Dai J, Allard WJ, Yeung KK (1999) Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal 13(1):35–39PubMedCrossRefGoogle Scholar
  4. 4.
    Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D (2008) Pregnancy-Associated Breast Cancer. Isr Med Assoc J 10:722–727PubMedGoogle Scholar
  5. 5.
    Pentheroudakis G (2008) Cancer and pregnancy. Ann Oncol. 19:38–39CrossRefGoogle Scholar
  6. 6.
    Høgdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20:4–8PubMedCrossRefGoogle Scholar
  7. 7.
    Stuırgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48(8):1151–1159Google Scholar
  8. 8.
    Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52(3):345–351PubMedCrossRefGoogle Scholar
  9. 9.
    Fry LC, Mönkemüller K, Malfertheiner P (2008) Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 393:883–890PubMedCrossRefGoogle Scholar
  10. 10.
    Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270PubMedCrossRefGoogle Scholar
  11. 11.
    Duffy MJ (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47(4):624–630PubMedGoogle Scholar
  12. 12.
    Touitou Y, Darbois Y, Bogdan A, Auzeby A, Keusseoglou S (1989) Tumour marker antigens during menses and pregnancy. Br J Cancer 60(3):419–420PubMedCrossRefGoogle Scholar
  13. 13.
    Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, van Kamp GJ, van Geijn HP, van Vugt JM (2001) Maternal serum Ca125 and Ca15–3 antigen levels in normal and pathological pregnancy. Fetal Diagn 16(3):166–172CrossRefGoogle Scholar
  14. 14.
    Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T (1989) Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol 160(3):563–566PubMedGoogle Scholar
  15. 15.
    Spitzer M, Kaushal N, Benjamin F (1998) Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 43(4):387–392PubMedGoogle Scholar
  16. 16.
    Botsis D, Sarandakou A, Kassanos D, Kontoravdis A, Rizos D, Protonotariou E, Phocas I, Creatsas G (1999) Breast cancer markers during normal pregnancy. Anticancer Res 19(4C):3539–3541PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Şerif Ercan
    • 1
    • 3
  • Özge Kaymaz
    • 2
  • Nihal Yücel
    • 1
  • Asuman Orçun
    • 1
  1. 1.Department of Clinical BiochemistryDr. Lutfi Kirdar Kartal Education and Research HospitalIstanbulTurkey
  2. 2.Department of Obstetrics and GynecologyDr. Lutfi Kirdar Kartal Education and Research HospitalIstanbulTurkey
  3. 3.IstanbulTurkey

Personalised recommendations